title: Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin: a multicenter, randomized, investigator-blinded study.
abstract: This multicenter, randomized, investigator-blinded study investigated the efficacy and tolerability of adapalene gel 0.1% plus clindamycin phosphate lotion 1%, compared with clindamycin plus vehicle for the treatment of mild to moderate acne vulgaris. A total of 249 patients applied clindamycin lotion twice daily and adapalene (125 patients) or vehicle gel (124 patients) once daily for 12 weeks. A significantly greater reduction of total (P <.001), inflammatory (P =.004) and noninflammatory lesions (P <.001) was seen in the clindamycin plus adapalene group than in the clindamycin plus vehicle group. These significant treatment effects were observed as early as week 4 for both noninflammatory and total lesion counts. Both treatment regimens were well tolerated. Although the worst scores for scaling (P <.05), dryness (P <.01), and stinging/burning (P <.05) were higher in the clindamycin plus adapalene group than in the clindamycin plus vehicle group in patients with moderate or severe irritation; in most cases these symptoms were of mild intensity.
authors.affiliation: Baylor College of Medicine, Dermatology Department, Houston, TX 77030, USA. jwolf@bcm.tmc.edu
authors.forename: John E
authors.initials: JE
authors.lastname: Wolf
authors.forename: David
authors.initials: D
authors.lastname: Kaplan
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Kraus
authors.forename: Keith H
authors.initials: KH
authors.lastname: Loven
authors.forename: Toivo
authors.initials: T
authors.lastname: Rist
authors.forename: Leonard J
authors.initials: LJ
authors.lastname: Swinyer
authors.forename: Michael D
authors.initials: MD
authors.lastname: Baker
authors.forename: Yin S
authors.initials: YS
authors.lastname: Liu
authors.forename: Janusz
authors.initials: J
authors.lastname: Czernielewski
mesh_terms: D000152:Acne Vulgaris / Q000175:diagnosis / Q000188:drug therapy*; D000068816:Adapalene; D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D002648:Child; D002981:Clindamycin / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000627:therapeutic use*; D011336:Probability; D012016:Reference Values; D012720:Severity of Illness Index; D016037:Single-Blind Method; D016896:Treatment Outcome
chemical_list: D009281:Naphthalenes; D000068816:Adapalene; D002981:Clindamycin